Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4223870 | 0.95 | TLR7 (0.47) | TLR7 | |
| SCHEMBL3359424 | 0.94 | TLR7 (0.50) | TLR7ADORA2AADORA2B | |
| SCHEMBL20275365 | 0.93 | TLR7 (0.53) | TLR7 | |
| SCHEMBL4126699 | 0.91 | TLR7 (0.49) | TLR7 | |
| SCHEMBL566897 | 0.89 | TLR7 (0.53) | TLR7 | |
| SCHEMBL728835 | 0.89 | TLR7 (0.50) | TLR7 | |
| SCHEMBL14151403 | 0.88 | TLR7 (0.55) | TLR7 | |
| SCHEMBL1241960 | 0.88 | TLR7 (0.49) | TLR7 | |
| SCHEMBL566854 | 0.88 | TLR7 (0.52) | TLR7 | |
| SCHEMBL2387756 | 0.88 | TLR7 (0.49) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651943-B1 | PURINE DERIVATIVES | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-03-22 | — | — | EP | disclosed |
| EP-2651943-B1 | PURINE DERIVATIVES | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-8895570-B2 | Purine derivatives | ASTRAZENECA AB (SE) | 2014-11-25 | — | — | US | disclosed |
| US-8895570-B2 | Purine derivatives | ASTRAZENECA AB (SE) | 2014-11-25 | — | — | US | disclosed |
| US-8895570-B2 | Purine derivatives | ASTRAZENECA AB (SE) | 2014-11-25 | — | — | US | disclosed |
| US-8865896-B2 | Method for preparing adenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-10-21 | — | — | US | disclosed |
| US-8865896-B2 | Method for preparing adenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-10-21 | — | — | US | disclosed |
| US-20130338174-A1 | PURINE DERIVATIVES | Sumitomo Pharma Co., Ltd. (JP) | 2013-12-19 | — | — | US | disclosed |
| EP-2651943-A1 | PURINE DERIVATIVES | Astrazeneca AB (SE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080730-A1 | PURINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | WO | disclosed |
| EP-2246353-A1 | METHOD FOR PRODUCING ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246353-A1 | METHOD FOR PRODUCING ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20090082332-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ABBOT PHILIP | 2009-03-26 | — | — | US | disclosed |
| EP-1928877-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | Astra Zeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007034173-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082332-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ADORA3, ADORA1, P2RX1 | TLR7 271/4885ADORA2A 4/4885ADORA2B 5/4885 |
| US-20130338174-A1 | PURINE DERIVATIVES | HPRT1, PNP, SLC29A1 | TLR7 288/4885ADORA2A 17/4885ADORA2B 45/4885 |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | TLR7 4/4885ADORA2A 25/4885ADORA2B 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.